Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced tod ...

Krystal Biotech, Inc. (KRYS) announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, KB407 and KB408, which are being developed in early-stage studies for treating rare respiratory diseases.Shares of the company were down 7.3% on Dec. 12 following the announcement of the news.KB407 is being developed in a phase I study for the treatment of cystic fibrosis (CF), while KB408 is being developed in a phase I study for treating alpha-1 antitrypsin deficiency (AATD).The la ...

A month has gone by since the last earnings report for Krystal Biotech, Inc. (KRYS) . Shares have added about 6.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Krystal Biotech due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Krystal Q3 Earnings and Sales Top Estim ...

PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences: Citi’s 2024 Global Healthcare Conference on December 3, 2024 in Miami, Florida; fireside chat scheduled for 8:45 am ET7th Annual Evercore HealthCONx Conference on December 4, 2024 in Coral Gable ...

PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning ...

Krystal Biotech (KRYS) reported third-quarter earnings per share of 91 cents, which beat the Zacks Consensus Estimate of 84 cents. In the year-ago quarter, the company incurred a loss of 67 cents per share.Revenues totaled $83.8 million, which beat the Zacks Consensus Estimate of $83 million. Revenues came in solely from the sales of Vyjuvek. In the year-ago quarter, revenues amounted to $8.6 million.Shares of Krystal have surged 37.8% year to date against the industry’s decline of 3.8%.Image Source: Zacks ...

Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025 French health authority approved pre-marketing early reimbursed access for B-VEC in France under the Accès Précoce (AP1) program; AP1 program for DEB patients access expected to start in 4Q 2024 Advancing Jeune Aesthetics' KB301 to Phase 2 aft ...

Core Viewpoint - Krystal Biotech, Inc. (KRYS) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Outlook - The Zacks rating reflects an upward trend in earnings estimates, which is crucial for stock price movements [1][3]. - Krystal Biotech is projected to earn $2.38 per share for the fiscal year ending December 2024, representing a year-over-year increase of 186.2% [5]. Earnings Estimate Revisions - Over the past three months, the Zacks Consensus Estimate for Krystal Biotech has increased by 45.3%, indicating a positive revision trend [5]. - The Zacks Rank system effectively utilizes earnings estimate revisions to classify stocks, with a strong historical performance of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [4]. Institutional Investor Influence - Changes in earnings estimates significantly impact stock valuations, as institutional investors adjust their fair value calculations based on these estimates, leading to stock price movements [3]. Market Positioning - The upgrade to Zacks Rank 2 places Krystal Biotech in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [6].

Krystal Biotech (NASDAQ: KRYS ) is gearing up for a very important Q4 of 2024 because it is gearing up to report data from two different studies at that time. The first study of which is by using a clinical candidate He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make info ...

Krystal Biotech, Inc. (KRYS) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate r ...